London School of Hygiene & Tropical Medicine

Rosiglitazone for Patients with Diabetes: Cardiovascular Outcomes Trial Findings

Stuart Pocock
Stuart Pocock

REFERENCE: ABSTRACT N Engl J Med 2007; 357: 28-381
STUART POCOCK, London School of Hygiene and Tropical Medicine
Reassuring findings about the safety of the anti-diabetic drug rosiglitazone have been published in the New England Journal of Medicine following an interim analysis of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) study. This latest publication follows a meta-analysis in June 2007 by Nissen and Wolski which raised doubt about the safety of the drug. Nicola Solomon spoke with the RECORD trial’s statistician, Stuart Pocock, to get the latest data from this largest study specifically designed to look at cardiovascular outcomes.

Similar Interviews

  • Meta-Analysis Proves Statins Help Patients With Diabetes
  • Colin Baigent REFERENCE: Lancet 371:117 January 11, 2008 COLIN BAIGENT, Oxford University

  • Audio Journal of Global Health Issues: Patient Power Best to Manage Diabetes
  • HILARY SELIGMAN, University of California, San Francisco REFERENCE: ABSTRACT Press Release, San Diego ACP 2007 Doctors can best help their patients with

  • Diabetic Patients: Some Benefits from Fibrates
  • Anthony Keech Among nearly 10 000 patients with maturity onset diabetes the use of fenofibrate to lower cholesterol produced a 24

    Post a comment

    Subscribe to Audio Medica Podcast